Pharming Group N.V.
PHAR
$12.97
-$0.12-0.92%
NASDAQ
| 03/31/2026 | 12/31/2025 | 06/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 22.44% | 24.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 22.44% | 24.13% |
| Cost of Revenue | -- | -- | -- | 14.31% | 19.69% |
| Gross Profit | -- | -- | -- | 23.49% | 24.70% |
| SG&A Expenses | -- | -- | -- | 9.45% | 6.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -116.43% | -111.51% |
| Total Operating Expenses | -- | -- | -- | 5.68% | 3.68% |
| Operating Income | -- | -- | -- | 136.09% | 112.48% |
| Income Before Tax | -- | -- | -- | 122.61% | 69.44% |
| Income Tax Expenses | -- | -- | -- | 675.90% | 1,005.03% |
| Earnings from Continuing Operations | -- | -- | -- | 36.11% | -32.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | 38.46% | -30.81% |
| EBIT | -- | -- | -- | 136.09% | 112.48% |
| EBITDA | -- | -- | -- | 292.00% | 180.64% |
| EPS Basic | -- | -- | -- | 34.80% | -31.93% |
| Normalized Basic EPS | -- | -- | -- | 92.40% | 97.01% |
| EPS Diluted | -- | -- | -- | 29.90% | -32.75% |
| Normalized Diluted EPS | -- | -- | -- | 92.40% | 97.01% |
| Average Basic Shares Outstanding | -- | -- | -- | -3.67% | -2.97% |
| Average Diluted Shares Outstanding | -- | -- | -- | -3.67% | -2.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |